Evidence map›Paper›PMID 40806561›Full record

ArticleInternational journal of molecular sciences2025

Anti-Ku Antibodies: Clinical Associations, Organ Damage, and Prognostic Implications in Connective Tissue Diseases.

Céline La, Julie Smet, Carole Nagant, Muhammad Soyfoo

Abstract read
In one paragraph

Article in International journal of molecular sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Céline LaDepartment of Rheumatology, Hôpital Erasme, Hôpital Universitaire de Bruxelles (HUB), 1070 Bruxelles, Belgium.ORCID 0000-0002-6065-2970
Julie SmetLaboratory of Immunology, Laboratoire Hospitalier Universitaire de Bruxelles, Université Libre de Bruxelles (LHUB-ULB), 1020 Bruxelles, Belgium.
Carole NagantLaboratory of Immunology, Laboratoire Hospitalier Universitaire de Bruxelles, Université Libre de Bruxelles (LHUB-ULB), 1020 Bruxelles, Belgium.ORCID 0000-0001-9755-5069
Muhammad SoyfooDepartment of Rheumatology, Hôpital Erasme, Hôpital Universitaire de Bruxelles (HUB), 1070 Bruxelles, Belgium.ORCID 0000-0002-9051-1810

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Anti-Ku antibodies are rare autoantibodies associated with connective tissue diseases (CTDs), but their clinical significance remains poorly understood due to limited studies. Semi-quantitative immunodot assays yield positive, negative, or borderline results, with the clinical relevance of borderline findings remaining unclear. The purpose of this study is to characterize the clinical spectrum of anti-Ku-positive patients and evaluate the clinical significance of anti-Ku-borderline results in CTD management. A retrospective cohort study was conducted at Hôpital Erasme, including all patients with anti-Ku-positive or borderline results, over a 10-year period. Clinical and biological data were collected from medical records and analyzed for disease associations, organ involvement, and outcomes. Among 47 anti-Ku-positive patients, systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS) were the most common diagnoses. Interstitial lung disease (ILD) occurred in 23.4% and renal involvement in 12.8% of patients. Cytopenia was significantly associated with glomerulonephritis. Organ damage, particularly pulmonary and renal involvement, correlated with increased mortality. In the borderline group (n = 33), SLE and SS remained the predominant diagnoses. During follow-up, three patients died (all with isolated ILD without associated CTD), one required chronic dialysis, and one underwent lung transplantation. ILD was present in 7/22 (31.8%) borderline patients, and renal involvement in 7/32 (21.9%). This study demonstrates significant associations between anti-Ku antibodies and organ damage, with increased mortality risk. The high prevalence of pulmonary and renal involvement in anti-Ku-borderline patients suggests that these results carry substantial clinical significance and should prompt comprehensive CTD evaluation. These findings support treating borderline anti-Ku results with the same clinical vigilance as positive results, given their similar association with severe organ involvement and adverse outcomes.

Indexed as

Antibodies, AntinuclearAutoantibodiesConnective Tissue DiseasesKu AutoantigenAdultAgedFemaleHumansLung Diseases, InterstitialLupus Erythematosus, SystemicMaleMiddle AgedPrognosisRetrospective StudiesSjogren's SyndromeAntibodies, AntinuclearAutoantibodiesKu AutoantigenXrcc6 protein, humananti-Ku antibodiesautoantibodiesborderline resultsconnective tissue diseasesinterstitial lung diseaseprognosis

Identifiers

PMID40806561
PMCPMC12347976

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.